2024

Goetze TO, Reichart A, Bankstahl US, Pauligk C, Loose M, Kraus TW, Elshafei M, Bechstein WO, Trojan J, Behrend M, Homann N, Venerito M, Bohle W, Varvenne M, Bolling C, Behringer DM, Kratz-Albers K, Siegler GM, Hozaeel W, Al-Batran SE. Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial. Ann Surg Oncol. 2024 Mar 8. doi: 10.1245/s10434-024-15011-7

Masetti M, Al-Batran SE, Goetze TO, Thuss-Patience P, Knorrenschild JR, Goekkurt E, Folprecht G, Ettrich TJ, Lindig U, Luley KB, Pink D, Dechow T, Sookthai D, Junge S, Loose M, Pauligk C, Lorenzen S. Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy. Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34894

Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, Yasui H, Yabusaki H, Afanasyev S, Park YK, Al-Batran SE, Yoshikawa T, Yanez P, Dib Bartolomeo M, Lonardi S, Tabernero J, Van Cutsem E, Janjigian YY, Oh DY, Xu J, Fang X, Shih CS, Bhagia P, Bang YJ; KEYNOTE-585 investigators. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024 Feb;25(2):212-224. doi: 10.1016/S1470-2045(23)00541-7

Goetze T, Gonzalez-Carmona MA, Kochen L, Agaoglu NB, Al-Batran SE, Habibzada T, Pons M, Brunner M, Ettrich TJ, Köhne CH, Roderburg C, Modest D. ADJUBIL: phase II study of adjuvant immunotherapy with STRIDE regimen with/without capecitabine in biliary tract cancers. Future Oncol. 2024 Feb;20(6):307-315. doi: 10.2217/fon-2023-0961.

Thuss-Patience P, Högner A, Goekkurt E, Stahl M, Kretzschmar A, Götze T, Stocker G, Reichardt P, Kullmann F, Pink D, Bartels P, Jarosch A, Hinke A, Schultheiß C, Paschold L, Stein A, Binder M. Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma: The Phase 2 RAP (AIO-STO-0218) Nonrandomized Controlled Trial. JAMA Netw Open. 2024 Jan 2;7(1):e2352830. doi: 10.1001/jamanetworkopen.2023.52830.

2023

Lorenzen S*, Götze TO*, Thuss-Patience P, Biebl M, Homann N, Schenk M, Lindig U, Heuer V, Kretzschmar A, Goekkurt E, Haag GM, Riera-Knorrenschild J, Bolling C, Hofheinz RD, Zhan T, Angermeier S, Ettrich TJ, Siebenhuener AR, Elshafei M, Bechstein WO, Gaiser T, Loose M, Sookthai D, Kopp C, Pauligk C, Al-Batran SE; AIO and SAKK Study Working Groups. Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial. J Clin Oncol. 2023 Nov 14:JCO2300975. doi: 10.1200/JCO.23.00975

Tintelnot J, Stein A, Al-Batran SE, Ettrich T, Götze T, Grün B, Haag GM, Heuer V, Hofheinz RD, Homann N, Bröring TS, Cruz MS, Kurreck A, Lorenzen S, Moosmann N, Müller C, Schuler M, Siegler G, Binder M, Gökkurt E. Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321). Front Oncol. 2023 Oct 16;13:1272175. doi: 10.3389/fonc.2023.1272175

Al-Batran SE, Mueller DW, Rafiyan MR, Kiselicki D, Atmaca A, Habibzada T, Mueller C, Brignone C, Triebel F, Loose M, Schaaf M, Sookthai D, Eickhoff R, Jaeger E, Goetze TO. A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology. ESMO Open. 2023 Sep 22;8(5):101623. doi: 10.1016/j.esmoop.2023.101623

Goetze TO, Stein A, Lorenzen S, Habibzada T, Goekkurt E, Herhaus P, Loose M, Sookthai D, Brulin T, Ihrig K, Pauligk C, Al-Batran SE. Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapy. Int J Cancer. 2023 Jul 16. doi: 10.1002/ijc.34652

Lorenzen S, Schwarz A, Pauligk C, Goekkurt E, Stocker G, Knorrenschild JR, Illerhaus G, Dechow T, Moehler M, Moulin JC, Pink D, Stahl M, Schaaf M, Goetze TO, Al-Batran SE. Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415). BMC Cancer. 2023 Jun 19;23(1):561. doi: 10.1186/s12885-023-11004-z

Ilson DH, Al-Batran SE. Preoperative chemoradiotherapy or perioperative chemotherapy for patients with gastro-oesophageal junction adenocarcinoma. Lancet Oncol. 2023 Jun;24(6):593-595. doi: 10.1016/S1470-2045(23)00244-9

Hess T, Maj C, Gehlen J, Borisov O, Haas SL, Gockel I, Vieth M, Piessen G, Alakus H, Vashist Y, Pereira C, Knapp M, Schüller V, Quaas A, Grabsch HI, Trautmann J, Malecka-Wojciesko E, Mokrowiecka A, Speller J, Mayr A, Schröder J, Hillmer AM, Heider D, Lordick F, Pérez-Aísa Á, Campo R, Espinel J, Geijo F, Thomson C, Bujanda L, Sopeña F, Lanas Á, Pellisé M, Pauligk C, Goetze TO, Zelck C, Reingruber J, Hassanin E, Elbe P, Alsabeah S, Lindblad M, Nilsson M, Kreuser N, Thieme R, Tavano F, Pastorino R, Arzani D, Persiani R, Jung JO, Nienhüser H, Ott K, Schumann RR, Kumpf O, Burock S, Arndt V, Jakubowska A, Ławniczak M, Moreno V, Martín V, Kogevinas M, Pollán M, Dąbrowska J, Salas A, Cussenot O, Boland-Auge A, Daian D, Deleuze JF, Salvi E, Teder-Laving M, Tomasello G, Ratti M, Senti C, De Re V, Steffan A, Hölscher AH, Messerle K, Bruns CJ, Sīviņš A, Bogdanova I, Skieceviciene J, Arstikyte J, Moehler M, Lang H, Grimminger PP, Kruschewski M, Vassos N, Schildberg C, Lingohr P, Ridwelski K, Lippert H, Fricker N, Krawitz P, Hoffmann P, Nöthen MM, Veits L, Izbicki JR, Mostowska A, Martinón-Torres F, Cusi D, Adolfsson R, Cancel-Tassin G, Höblinger A, Rodermann E, Ludwig M, Keller G, Metspalu A, Brenner H, Heller J, Neef M, Schepke M, Dumoulin FL, Hamann L, Cannizzaro R, Ghidini M, Plaßmann D, Geppert M, Malfertheiner P, Gehlen O, Skoczylas T, Majewski M, Lubiński J, Palmieri O, Boccia S, Latiano A, Aragones N, Schmidt T, Dinis-Ribeiro M, Medeiros R, Al-Batran SE, Leja M, Kupcinskas J, García-González MA, Venerito M, Schumacher J. Dissecting the genetic heterogeneity of gastric cancer. EBioMedicine. 2023 May 18;92:104616. doi: 10.1016/j.ebiom.2023.104616

Le DT, Diaz LA Jr, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O’Neil BH, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Élez E, Al-Batran SE, Boland PM, Cui Y, Leconte P, Marinello P, André T. Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164. Eur J Cancer. 2023 Jun;186:185-195. doi: 10.1016/j.ejca.2023.02.016

Goetze TO, Hofheinz RD, Gaiser T, Schmalenberg H, Strumberg D, Goekkurt E, Angermeier S, Zander T, Kopp HG, Pink D, Siegler G, Schenk M, de Vita F, Galizia G, Maiello E, Bechstein WO, Elshafei M, Loose M, Sookthai D, Brulin T, Pauligk C, Homann N, Al-Batran SE. Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM. Int J Cancer. 2023 Mar 8. doi: 10.1002/ijc.34495

2022

Tintelnot J, Ristow I, Sauer M, Simnica D, Schultheiß C, Scholz R, Goekkurt E, von Wenserski L, Willscher E, Paschold L, Lorenzen S, Riera-Knorrenschild J, Depenbusch R, Ettrich TJ, Dörfel S, Al-Batran SE, Karthaus M, Pelzer U, Hinke A, Bauer M, Massa C, Seliger B, Wickenhauser C, Bokemeyer C, Hegewisch-Becker S, Binder M, Stein A. Translational analysis and final efficacy of the AVETUX trial – Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer. Front Oncol. 2022 Dec 20;12:993611. doi: 10.3389/fonc.2022.993611

Goetze TO, Al-Batran SE. Perspectives on the Management of Oligometastatic Disease in Esophago-Gastric Cancer. Cancers (Basel). 2022 Oct 23;14(21):5200. doi: 10.3390/cancers14215200

Stein A, Paschold L, Tintelnot J, Goekkurt E, Henkes SS, Simnica D, Schultheiss C, Willscher E, Bauer M, Wickenhauser C, Thuss-Patience P, Lorenzen S, Ettrich T, Riera-Knorrenschild J, Jacobasch L, Kretzschmar A, Kubicka S, Al-Batran SE, Reinacher-Schick A, Pink D, Sinn M, Lindig U, Hiegl W, Hinke A, Hegewisch-Becker S, Binder M. Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial. JAMA Oncol. 2022 Aug 1;8(8):1150-1158. doi: 10.1001/jamaoncol.2022.2228

Hofheinz RD, Merx K, Haag GM, Springfeld C, Ettrich T, Borchert K, Kretzschmar A, Teschendorf C, Siegler G, Ebert MP, Goekkurt E, Mahlberg R, Homann N, Pink D, Bechstein W, Reichardt P, Flach H, Gaiser T, Battmann A, Oduncu FS, Loose M, Sookthai D, Pauligk C, Goetze TO, Al-Batran SE. FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group. J Clin Oncol. 2022 Jun 16:JCO2200380. doi: 10.1200/JCO.22.00380

Fischer LE, Stintzing S, von Weikersthal LF, Modest DP, Decker T, Kiani A, Kaiser F, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Giessen-Jung C, Uhlig J, Peuser B, Denzlinger C, Stahler A, Weiss L, Heinrich K, Held S, Jung A, Kirchner T, Heinemann V. Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3. Br J Cancer. 2022 Sep;127(5):836-843. doi: 10.1038/s41416-022-01854-y.

Janjigian YY, Van Cutsem E, Muro K, Wainberg Z, Al-Batran SE, Hyung WJ, Molena D, Marcovitz M, Ruscica D, Robbins SH, Negro A, Tabernero J. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. Future Oncol. 2022 May 10. doi: 10.2217/fon-2022-0093

Haag GM, Springfeld C, Grün B, Apostolidis L, Zschäbitz S, Dietrich M, Berger A-K, Weber TF, Zoernig I, Schaaf M, Waberer L, Mueller DW, Al-Batran SE, Halama N, Jaeger D. Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer – The PICCASSO phase I trial. Eur J Cancer 2022; 167:112-122. doi:10.1016/j.ejca.2022.03.017

Lorenzen S, Thuss-Patience P, Pauligk C, Gökkurt E, Ettrich T, Lordick F, Stahl M, Reichardt P, Sökler M, Pink D, Probst S, Hinke A, Goetze TO, Al-Batran SE. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. Eur J Cancer. 2022 Apr;165:48-57. doi: 10.1016/j.ejca.2022.01.015

Högner A, Al-Batran SE, Siveke JT, Lorenz M, Bartels P, Breithaupt K, Malfertheiner P, Homann N, Stein A, Gläser D, Tamm I, Hinke A, Vogel A, Thuss- Patience P; PaFLO investigators. Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase-II study-The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510. Int J Cancer. 2022 Mar 15;150(6):1007-1017. doi: 10.1002/ijc.33864

2021

Goetze TO, Piso P, Lorenzen S, Bankstahl US, Pauligk C, Elshafei M, Amato G, Reim D, Bechstein WO, Königsrainer A, Mönig SP, Rau B, Schwarzbach M, Al-Batran SE. Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma – the phase III “PREVENT”- (FLOT9) trial of the AIO /CAOGI /ACO. BMC Cancer. 2021 Oct 29;21(1):1158. doi: 10.1186/s12885-021-08872-8

Catenacci DV, Chao J, Muro K, Al-Batran SE, Klempner SJ, Wainberg ZA, Shah MA, Rha SY, Ohtsu A, Liepa AM, Knoderer H, Chatterjee A, Van Cutsem E. Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/ Gastroesophageal Junction Adenocarcinoma. Oncologist. 2021 Oct;26(10):e1704-e1729. doi: 10.1002/onco.13907

Hofheinz RD, Hegewisch-Becker S, Kunzmann V, Thuss-Patience P, Fuchs M, Homann N, Graeven U, Schulte N, Merx K, Pohl M, Held S, Keller R, Tannapfel A, Al-Batran SE. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. Int J Cancer. 2021 Sep 15;149(6):1322-1331. doi: 10.1002/ijc.33696

Hempel L, de Oliveira JV, Gaumann A, Milani V, Schweneker K, Schenck K, Fleischmann B, Philipp P, Mederle S, Garg A, Piehler A, Gandorfer B, Schick C, Kleespies A, Sellmann L, Bartels M, Goetze TO, Stein A, Goekkurt E, Pfitzner L, Robert S, Hempel D. Landscape of Biomarkers and Actionable Gene Alterations in Adenocarcinoma of GEJ and Stomach-A Real World Data Analysis. Cancers (Basel). 2021 Sep 3;13(17):4453. doi: 10.3390/cancers13174453

Stein A, Simnica D, Schultheiß C, Scholz R, Tintelnot J, Gökkurt E, von Wenserski L, Willscher E, Paschold L, Sauer M, Lorenzen S, Riera-Knorrenschild J, Depenbusch R, Ettrich TJ, Dörfel S, Al-Batran SE, Karthaus M, Pelzer U, Waberer L, Hinke A, Bauer M, Massa C, Seliger B, Wickenhauser C, Bokemeyer C, Hegewisch-Becker S, Binder M. PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. J Immunother Cancer. 2021 Jul;9(7):e002844. doi: 10.1136/jitc-2021-002844

Christopoulos P, Bozorgmehr F, Brückner L, Chung I, Krisam J, Schneider MA, Stenzinger A, Eickhoff R, Mueller DW, Thomas M. Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial. BMC Cancer. 2021 Jun 28;21(1):743

Lordick F, Al-Batran SE, Ganguli A, Morlock R, Sahin U, Türeci Ö. Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma. Gastric Cancer. 2021 May;24(3):721-730. doi: 10.1007/s10120-020-01153-6

Wainberg ZA, Fuchs CS, Tabernero J, Shitara K, Muro K, Van Cutsem E, Bang YJ, Chung HC, Yamaguchi K, Varga E, Chen JS, Hochhauser D, Thuss-Patience P, Al-Batran SE, Garrido M, Kher U, Shih CS, Shah S, Bhagia P, Chao J. Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10. Clin Cancer Res. 2021 Apr 1;27(7):1923-1931. doi: 10.1158/1078-0432.CCR-20-2980

Al-Batran SE, Hofheinz RD, Reichart A, Pauligk C, Schönherr C, Schlag R, Siegler G, Dörfel S, Koenigsmann M, Zahn MO, Schubert J, Aldaoud A, Höffkes HG, Schulz H, Hahn L, Uhlig J, Blau W, Stauch M, Weniger J, Wolf M, Jacobasch L, Bildat S, Wehmeyer J, Homann N, Trojan J, Waidmann O, Fietz T, Feustel HP, Groschek M, Wierecky J, Waibel K, Mahlmann S, Schwindel U, Peters U, Schuch G, Pink D, Eschenburg H, Wörns MA, Harich HD, von Weikersthal LF, Däßler KU, Behringer DM, Messmann H, Kretzschmar A, Gallmeier E, Forstbauer H, Kunzmann V, Papke J, Büchner-Steudel P, Vehling-Kaiser U, Springfeld C, Vogel A, Ettrich TJ, Schaaf M, Hausen GZ, Goetze TO; Arbeitsgemeinschaft Internistische Onkologie (AIO). Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry. Int J Cancer. 2021 Mar 15;148(6):1478-1488. doi: 10.1002/ijc.33336

Heinemann V, von Weikersthal LF, Decker T, Kiani A, Kaiser F, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Moehler M, Scheithauer W, Held S, Miller-Phillips L, Modest DP, Jung A, Kirchner T, Stintzing S. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. Br J Cancer. 2021 Feb;124(3):587-594. doi: 10.1038/s41416-020-01140-9

2020

Sylvie Lorenzen, Jorge Riera Knorrenschild, Claudia Pauligk, Susanna Hegewisch-Becker, Jörg Seraphin, Peter Thuss-Patience, Hans-Georg Kopp, Tobias Dechow, Arndt Vogel, Kim Barbara Luley, Daniel Pink, Michael Stahl, Frank Kullmann, Holger Hebart, Jens Siveke, Matthias Egger, Nils Homann, Stephan Probst, Thorsten Oliver Goetze, Salah-Eddin Al-Batran. Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). Int J Cancer. 2020 Nov 1;147(9):2493-2502. doi: 10.1002/ijc.33025. Epub 2020 May 7.

Sylvie Lorenzen, Alexander Biederstädt, Ulrich Ronellenfitsch, Christoph Reißfelder, Stefan Mönig, Frederik Wenz, Claudia Pauligk, Martin Walker, Salah-Eddin Al-Batran, Bernhard Haller, Ralf-Dieter Hofheinz. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction – a randomized phase III joint study of the AIO, ARO and DGAV. BMC Cancer.2020 Sep 15;20(1):886. doi: 10.1186/s12885-020-07388-x.

Salah-Eddin Al-Batran, Enno Moorahrend, Christoph Maintz, Thorsten O Goetze, Dirk Hempel, Peter Thuss-Patience, Vincent E Gaillard, Susanna Hegewisch-Becker. Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. Oncologist. 2020 Aug;25(8):e1181-e1187. doi: 10.1634/theoncologist.2020-0109. Epub 2020 Jun 4.

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Annette Reichardt, Barbara Hermes, Jochen Schütte, Silke Cameron, Peter Hohenberger, Philipp J Jost, Salah-Eddin Al-Batran, Lars H Lindner, Sebastian Bauer, Eva Wardelmann, Bengt Nilsson, Raija Kallio, Panu Jaakkola, Jouni Junnila, Thor Alvegård, Peter Reichardt. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up. JAMA Oncol .2020 Aug 1;6(8):1241-1246. doi: 10.1001/jamaoncol.2020.2091.

Joseph Tintelnot, Eray Goekkurt, Mascha Binder, Peter Thuss-Patience, Sylvie Lorenzen, Jorge Riera Knorrenschild, Albrecht Kretzschmar, Thomas Ettrich, Udo Lindig, Lutz Jacobasch, Daniel Pink, Salah-Eddin Al-Batran, Axel Hinke, Susanna Hegewisch-Becker, Sven Nilsson, Carsten Bokemeyer, Alexander Stein. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma – the randomized phase 2 INTEGA trial (AIO STO 0217). BMC Cancer. 2020 Jun 1;20(1):503. doi: 10.1186/s12885-020-06958-3.

Matthias Kloor, Miriam Reuschenbach, Claudia Pauligk, Julia Karbach, Mohammad-Reza Rafiyan, Salah-Eddin Al-Batran, Mirjam Tariverdian, Elke Jaeger, Magnus von Knebel Doeberitz. A Phase I/IIa Trial of a Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers. Clin Cancer Res. 2020 Jun 15; clincanres.3517.2019. doi: 10.1158/1078-0432.CCR-19-3517. Online ahead of print.

Joseph Tintelnot, Eray Goekkurt, Mascha Binder, Peter Thuss-Patience, Sylvie Lorenzen, Jorge Riera Knorrenschild, Albrecht Kretzschmar, Thomas Ettrich, Udo Lindig, Lutz Jacobasch, Daniel Pink, Salah-Eddin Al-Batran, Axel Hinke, Susanna Hegewisch-Becker, Sven Nilsson, Carsten Bokemeyer, Alexander Stein. Ipilimumab or FOLFOX With Nivolumab and Trastuzumab in Previously Untreated HER2-positive Locally Advanced or Metastatic EsophagoGastric Adenocarcinoma – The Randomized Phase 2 INTEGA Trial (AIO STO 0217). BMC Cancer. 2020 Jun 1;20(1):503. doi: 10.1186/s12885-020-06958-3.

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Annette Reichardt, Barbara Hermes, Jochen Schütte , Silke Cameron , Peter Hohenberger , Philipp J Jost , Salah-Eddin Al-Batran , Lars H Lindner , Sebastian Bauer , Eva Wardelmann , Bengt Nilsson , Raija Kallio , Panu Jaakkola , Jouni Junnila , Thor Alvegård , Peter Reichardt. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up. JAMA Oncol. 2020 May 29;e202091. doi: 10.1001/jamaoncol.2020.2091. Online ahead of print.

Sylvie Lorenzen, Jorge Riera Knorrenschild, Claudia Pauligk, Susanna Hegewisch-Becker, Jörg Seraphin, Peter Thuss-Patience, Hans-Georg Kopp, Tobias Dechow,  Arndt Vogel, Kim Barbara Luley, Daniel Pink, Michael Stahl, Frank Kullmann, Holger Hebart, Jens Siveke, Matthias Egger, Nils Homann, Stephan Probst, Thorsten Oliver Goetze, Salah-Eddin Al-Batran. Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/ platinum-containing regimen (RADPAC). Int J Cancer. 2020 Apr 27. doi: 10.1002/ijc.33025. Online ahead of print.

Salah-Eddin Al-Batran, Enno Moorahrend, Christoph Maintz, Thorsten O Goetze, Dirk Hempel, Peter Thuss-Patience, Vincent E Gaillard, Susanna Hegewisch-Becker. Clinical Practice Observation of Trastuzumab in Patients With Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. Oncologist. 2020 Apr 20. doi: 10.1634/theoncologist.2020-0109. Online ahead of print.

E Van Cutsem, K Muro, D Cunningham, G Bodoky, A Sobrero, S Cascinu, J Ajani, S C Oh, S E Al-Batran , Z A Wainberg, S R Wijayawardana, S Melemed, D Ferry, R R Hozak, A Ohtsu, RAINBOW Investigators. Biomarker Analyses of Second-Line Ramucirumab in Patients With Advanced Gastric Cancer From RAINBOW, a Global, Randomized, Double-Blind, Phase 3 Study. Eur J Cancer. 2020 Mar;127:150-157. doi: 10.1016/j.ejca.2019.10.026. Epub 2020 Jan 31.

M Moehler, A Maderer, P C Thuss-Patience, B Brenner, J Meiler, T J Ettrich, R-D Hofheinz, S E Al-Batran, A Vogel, L Mueller, M P Lutz, F Lordick, M Alsina, K Borchert, R Greil, W Eisterer, A Schad, J Slotta-Huspenina, E Van Cutsem, S Lorenzen. Cisplatin and 5-fluorouracil With or Without Epidermal Growth Factor Receptor Inhibition Panitumumab for Patients With Non-Resectable, Advanced or Metastatic Oesophageal Squamous Cell Cancer: A Prospective, Open-Label, Randomised Phase III AIO/EORTC Trial (POWER). Ann Oncol. 2020 Feb;31(2):228-235. doi: 10.1016/j.annonc.2019.10.018. Epub 2019 Dec 16.

Van Cutsem E, Muro K, Cunningham D, Bodoky G, Sobrero A, Cascinu S, Ajani J, Oh SC, Al-Batran SE, Wainberg ZA, Wijayawardana SR, Melemed S, Ferry D, Hozak RR, Ohtsu A; RAINBOW Investigators. Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study. Eur J Cancer. 2020 Mar;127:150-157. doi: 10.1016/j.ejca.2019.10.026. Epub 2020 Jan 31.

Goetze TO, Bechstein WO, Bankstahl US, Keck T, Königsrainer A, Lang SA, Pauligk C, Piso P, Vogel A, Al-Batran SE. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) – a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO/ CALGP/ ACO- GAIN-trial. BMC Cancer. 2020 Feb 14;20(1):122. doi: 10.1186/s12885-020-6610-4.

Al-Batran SE, Pauligk C, Götze TO. Perioperative chemotherapy for gastric cancer in FLOT4 – Authors’ reply. Lancet. 2020 Jan 11;395(10218):e4. doi: 10.1016/S0140-6736(19)32516-4.

2019

Moehler M, Al-Batran SE, Andus T, Arends J, Arnold D, Baretton G, Bornschein J, Budach W, Daum S, Dietrich C, Ebert M, Fischbach W, Flentje M, Gockel I, Grenacher L, Haier J, Höcht S, Jakobs R, Jenssen C, Kade B, Kanzler S, Langhorst J, Link H, Lordick F, Lorenz D, Lorenzen S, Lutz M, Messmann H, Meyer HJ, Mönig S, Ott K, Quante M, Röcken C, Schlattmann P, Schmiegel WH, Schreyer A, Tannapfel A, Thuss-Patience P, Weimann A, Unverzagt S. S3-Leitlinie Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und des ösophagogastralen Übergangs – Langversion 2.0 – August 2019. AWMF-Registernummer: 032/009OL. Z Gastroenterol. 2019 Dec;57(12):1517-1632. doi: 10.1055/a-1018-2516. Epub 2019 Dec 11. [Article in German]

Moehler M, Maderer A, Thuss-Patience PC, Brenner B, Meiler J, Ettrich TJ, Hofheinz RD, Al-Batran SE, Vogel A, Mueller L, Lutz MP, Lordick F, Alsina M, Borchert K, Greil R, Eisterer W, Schad A, Slotta-Huspenina J, Van Cutsem E, Lorenzen S. Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). Ann Oncol. 2020 Feb;31(2):228-235. doi: 10.1016/j.annonc.2019.10.018. Epub 2019 Dec 16.

Stintzing S, Wirapati P, Lenz HJ, Neureiter D, Fischer von Weikersthal L, Decker T, Kiani A, Kaiser F, Al-Batran S, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Moehler M, Scheithauer W, Held S, Modest DP, Jung A, Kirchner T, Aderka D, Tejpar S, Heinemann V. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. Ann Oncol. 2019 Nov 1;30(11):1796-1803. doi: 10.1093/annonc/mdz387.

Türeci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019 Sep;30(9):1487-1495. doi: 10.1093/annonc/mdz199. Epub 2019 Dec 12

Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O’Neil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland PM, Crocenzi T, Atreya CE, Cui Y, Dai T, Marinello P, Diaz LA Jr, André T. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2019 Nov 14:JCO1902107. doi: 10.1200/JCO.19.02107. [Epub ahead of print]

Koch C, Reitz C, Schreckenbach T, Eichler K, Filmann N, Al-Batran SE, Götze T, Zeuzem S, Bechstein WO, Kraus T, Bojunga J, Düx M, Trojan J, Blumenstein I. Sarcopenia as a prognostic factor for survival in patients with locally advanced gastroesophageal adenocarcinoma. PLoS One. 2019 Oct 22;14(10):e0223613. doi: 10.1371/journal.pone.0223613. eCollection 2019.

Lorenzen S, Stahl M, Hofheinz RD, Al-Batran SE, Lordick F. Influence of Taxanes on Treatment Sequence in Gastric Cancer. Oncol Res Treat. 2019 Oct 21:1-6. doi: 10.1159/000503428. [Epub ahead of print]

Fonkeu Y, Kraynyukova N, Hafner AS, Kochen L, Sartori F, Schuman EM, Tchumatchenko T. How mRNA Localization and Protein Synthesis Sites Influence Dendritic Protein Distribution and Dynamics. Neuron. 2019 Jul 23. pii: S0896-6273(19)30572-0. doi: 10.1016/j.neuron.2019.06.022. [Epub ahead of print]

Gaiser MR, Lorenzen S, Merx K, Trojan J, Ocvirk J, Ettrich TJ, Al-Batran SE, Schulz H, Homann N, Feustel HP, Schatz M, Kripp M, Schulte N, Heeger S, Vlassak S, Koch W, Hofheinz RD.  Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score. Cancer Med. 2019 Aug;8(9):4169-4175. doi: 10.1002/cam4.2132. Epub 2019 Jun 14.

Goetze TO, Al-Batran SE, Berlth F, Hoelscher AH.  Multimodal Treatment Strategies in Esophagogastric Junction Cancer: a Western Perspective.  J Gastric Cancer. 2019 Jun;19(2):148-156. doi: 10.5230/jgc.2019.19.e19. Epub 2019 May 24

Türeci O; Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M. A multicentre, phase 2a study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019 Jun 26. pii: mdz199. doi: 10.1093/annonc/mdz199. [Epub ahead of print]

Chiorean EG, Cheung WY, Giordano G, Kim G, Al-Batran SE. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review. Ther Adv Med Oncol. 2019 May 19;11:1758835919850367. doi: 10.1177/1758835919850367. eCollection 2019

Lin D, Khan U, Goetze TO, Reizine N, Goodman KA, Shah MA, Catenacci DV, Al-Batran SE, Posey JA. Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management? Am Soc Clin Oncol Educ Book. 2019 Jan;39:e88-e95. doi: 10.1200/EDBK_236827. Epub 2019 May 17.

Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019 Apr 10. pii: S0140-6736(18)32557-1. doi: 10.1016/S0140-6736(18)32557-1. [Epub ahead of print]

Mockett BG, Guévremont D, Elder MK, Parfitt KD, Peppercorn K, Morrissey J, Singh A, Hintz TJ, Kochen L, Tom Dieck S, Schuman E, Tate WP, Williams JM, Abraham WC. Glutamate Receptor Trafficking and Protein Synthesis Mediate the Facilitation of LTP by Secreted Amyloid Precursor Protein-Alpha. J Neurosci. 2019 Apr 24;39(17):3188-3203. doi: 10.1523/JNEUROSCI.1826-18.2019. Epub 2019 Feb 25.

Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran SE, Van Cutsem E, Ilson DH, Alsina M, Chau I, Lacy J, Ducreux M, Mendez GA, Alavez AM, Takahari D, Mansoor W, Enzinger PC, Gorbounova V, Wainberg ZA, Hegewisch-Becker S, Ferry D, Lin J, Carlesi R, Das M, Shah MA; RAINFALL Study Group. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Mar;20(3):420-435. doi: 10.1016/S1470-2045(18)30791-5. Epub 2019 Feb 1.

Chau I, Fuchs CS, Ohtsu A, Barzi A, Liepa AM, Cui ZL, Hsu Y, Al-Batran SE. Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials. Eur J Cancer. 2019 Jan;107:115-123. doi: 10.1016/j.ejca.2018.11.013. Epub 2018 Dec 14.

2018

Roca-Ferrer J, Pujols L, Pérez-González M, Alobid I, Callejas B, Vicens-Artés S, Fuentes M, Valero A, Picado C,Castor D, Nguyen D, Mullol J. Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers. Allergy Asthma Clin Immunol. 2018 Dec 18;14:86. doi: 10.1186/s13223-018-0311-4. eCollection 2018.

Gaiser MR, Lorenzen S, Merx K, Trojan J, Ocvirk J, Ettrich TJ, Al-Batran SE, Schulz H, Homann N, Feustel HP, Schatz M, Kripp M, Schulte N, Heeger S, Vlassak S, Koch W, Hofheinz RD. Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: A post hoc analysis of the EVITA trial. Ann Oncol. 2018 Oct 11. doi: 10.1093/annonc/mdy451. [Epub ahead of print].

Mueller DW, Goetze TO, Eickhoff R, Reichart A, Al-Batran SE. The “INSIGHT” trial: An explorative, open-labeled phase I study to evaluate the feasibility and safety of intra-tumoral, intra-peritoneal, and subcutaneous injections with IMP321 (LAG-3Ig fusion protein) for advanced stage solid tumor entities. Journal of Clinical Oncology 2018 36:15_suppl, TPS3129-TPS3129

Amato G, Romano G, Puleio R, Agrusa A, Goetze T, Gulotta E, Gordini L, Erdas E, Calò P. Neomyogenesis in 3D Dynamic Responsive Prosthesis for Inguinal Hernia Repair. Artif Organs. 2018 Oct 14

Gutt C, Jenssen C, Barreiros AP, Götze TO, Stokes CS, Jansen PL, Neubrand M, Lammert F; für die Teilnehmer der Konsensuskonferenz; Deutsche Gesellschaft für Innere Medizin e.V. (DGIM); Österreichische Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH); Schweizer Gesellschaft für Gastroenterologie (SGH); Gesellschaft für Humangenetik (GfH); Deutsche Gesellschaft für Ultraschall in der Medizin (DEGUM); Deutsche Gesellschaft für Chirurgie (DGCH); Institut für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTIG; beratende Funktion ohne Stimmrecht); Deutsche Arbeitsgemeinschaft zum Studium der Leber (GASL); Deutsche Röntgengesellschaft (DRG); Deutsche Leberhilfe e. V. [Updated S3-Guideline for Prophylaxis, Diagnosis and Treatment of Gallstones. German Society for Digestive and Metabolic Diseases (DGVS) and German Society for Surgery of the Alimentary Tract (DGAV) – AWMF Registry 021/008]. Z Gastroenterol. 2018 Aug;56(8):912-966

Lu Y, Rafiq A, Zhang Z, Aslani F, Fijak M, Lei T, Wang M, Kumar S, Klug J, Bergmann M, Chakraborty T, Meinhardt A, Bhushan S. Uropathogenic Escherichia coli virulence factor hemolysin A causes programmed cell necrosis by altering mitochondrial dynamics. FASEB J. 2018 Aug;32(8):4107-4120. doi: 10.1096/fj.201700768R

Hegewisch-Becker S, Nöpel-Dünnebacke S, Hinke A, Graeven U, Reinacher-Schick A, Hertel J, Lerchenmüller CA, Killing B, Depenbusch R, Al-Batran SE, Lange T, Dietrich G, Tannapfel A, Arnold D. Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial. Eur J Cancer. 2018 Sep;101:105-113. doi: 10.1016/j.ejca.2018.06.015. Epub 2018 Jul 20.

Bang YJ, Ruiz EY, Van Cutsem E, Lee KW, Wyrwicz L, Schenker M, Alsina M, Ryu MH, Chung HC, Evesque L, Al-Batran SE, Park SH, Lichinitser M, Boku N, Moehler MH, Hong J, Xiong H, Hallwachs R, Conti I, Taieb J. Phase 3, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment for patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018 Jul 24. doi: 10.1093/annonc/mdy264. [Epub ahead of print]

Knödler M, Körfer J, Kunzmann V, Trojan J, Daum S, Schenk M, Kullmann F, Schroll S, Behringer D, Stahl M, Al-Batran SE, Hacker U, Ibach S, Lindhofer H, Lordick F. Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer. Br J Cancer. 2018 Jul 10. doi: 10.1038/s41416-018-0150-6. [Epub ahead of print]

Fornaro L, Vasile E, Aprile G, Goetze TO, Vivaldi C, Falcone A, Al-Batran SE. Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions. Cancer Treat Rev. 2018 Jun 18;69:90-100. doi: 10.1016/j.ctrv.2018.06.012. [Epub ahead of print]

Goetze TO, Al-Batran SE, Pabst U, Reymond M, Tempfer C, Bechstein WO, Bankstahl U, Gockel I, Königsrainer A, Kraus T, Mönig SP, Rau B, Schwarzbach M, Piso P. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in combination with standard of care chemotherapy in primarily untreated chemo naïve upper gi-adenocarcinomas with peritoneal seeding – a phase II/III trial of the AIO/CAOGI/ACO.  Pleura Peritoneum. 2018 Jun 8;3(2):20180113. doi: 10.1515/pp-2018-0113. eCollection 2018 Jun 1.

Goetze TO, Al-Batran SE, Chevallay M, Mönig SP. Multimodal treatment in locally advanced gastric cancer. Updates Surg. 2018 Jun;70(2):173-179. doi: 10.1007/s13304-018-0539-z. Epub 2018 Jun 26.

Dörrbaum AR, Kochen L, Langer JD, Schuman EM. Local and global influences on protein turnover in neurons and glia. Elife. 2018 Jun 19;7. pii: e34202. doi: 10.7554/eLife.34202.

Nagel M, Schulz J, Maderer A, Goepfert K, Gehrke N, Thomaidis T, Thuss-Patience PC, Al-Batran SE, Hegewisch-Becker S, Grimminger P, Galle PR, Möhler M, Schattenberg JM. Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial. Tumour Biol. 2018 Mar;40(3):1010428318764007. doi: 10.1177/1010428318764007.

Hofheinz RD, Lorenzen S, Trojan J, Ocvirk J, Ettrich TJ, Al-Batran SE, Schulz H, Homann N, Feustel HP, Schatz M, Kripp M, Schulte N, Tetyusheva M, Heeger S, Vlassak S, Merx K. EVITA – A double-blind, vehicle controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity. Ann Oncol. 2018 Jan 18. doi: 10.1093/annonc/mdy015. [Epub ahead of print]

Hammerer P, Al-Batran SE, Windemuth-Kieselbach C, Keller M, Hofheinz RD. PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study. World J Urol. 2018 Jan 5. doi: 10.1007/s00345-017-2138-x. [Epub ahead of print]

Deckmann K, Rafiq A, Erdmann C, Illig C, Durschnabel M, Wess J, Weidner W, Bschleipfer T, Kummer W. Muscarinic receptors 2 and 5 regulate bitter response of urethral brush cells via negative feedback. FASEB J. 2018 Jun;32(6):2903-2910. doi: 10.1096/fj.201700582R. Epub 2018 Jan 17

Falkenstein TA, Götze TO, Ouaissi M, Tempfer CB, Giger-Pabst U, Demtröder C. First Clinical Data of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) as Salvage Therapy for Peritoneal Metastatic Biliary Tract Cancer. Anticancer Res. 2018 Jan;38(1):373-378.

2017

Al-Batran SE, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, Novotny A, Pauligk C, Homann N, Jungbluth T, Reissfelder C, Caca K, Retter S, Horndasch E, Gumpp J, Bolling C, Fuchs KH, Blau W, Padberg W, Pohl M, Wunsch A, Michl P, Mannes F, Schwarzbach M, Schmalenberg H, Hohaus M, Scholz C, Benckert C, Knorrenschild JR, Kanngießer V, Zander T, Alakus H, Hofheinz RD, Roedel C, Shah MA, Sasako M, Lorenz D, Izbicki J, Bechstein WO, Lang H, Moenig SP. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer. 2017 Dec 28;17(1):893. doi: 10.1186/s12885-017-3918-9.

Schmalenberg H, Al-Batran SE, Pauligk C, Zander T, Reichart A, Lindig U, Kleiß M, Müller L, Bolling C, Seufferlein T, Reichardt P, Kullmann F, Eschenburg H, Schmittel A, Egger M, Block A, Goetze TO. CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach. J Cancer Res Clin Oncol. 2017 Dec 28. doi: 10.1007/s00432-017-2565-5. [Epub ahead of print]

Spoerl S, Novotny A, Al-Batran SE, Lordick F, Thuss-Patience P, Pauligk C, Haller B, Feith M, Lorenzen S. Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma. Eur J Cancer. 2017 Dec 19;90:26-33. doi: 10.1016/j.ejca.2017.11.020. [Epub ahead of print]

Modest DP, Stintzing S, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Moehler M, Holch JW, von Einem JC, Held S, Heinemann V. Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306). Oncotarget. 2017 Nov 11;8(62):105749-105760. doi: 10.18632/oncotarget.22396. eCollection 2017 Dec 1.

Holch JW, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Kullmann F, Scheithauer W, Scholz M, Müller S, Link H, Rost A, Höffkes HG, Moehler M, Lindig RU, Miller-Phillips L, Kirchner T, Jung A, von Einem JC, Modest DP, Heinemann V. Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial. Int J Cancer. 2017 Oct 19. doi: 10.1002/ijc.31114. [Epub ahead of print]

Honecker F, Harbeck N, Schnabel C, Wedding U, Waldenmaier D, Saupe S, Jäger E, Schmidt M, Kreienberg R, Müller L, Otremba B, Dorn J, Warm M, Al-Batran SE, de Wit M; PELICAN investigators. Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial. J Geriatr Oncol. 2017 Oct 18. pii: S1879-4068(17)30195-9. doi: 10.1016/j.jgo.2017.09.009. [Epub ahead of print]

Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, Tejani MA, Udrea AA, Tehfe M, De Vita F, Turkington C, Tang R, Ang A, Zhang Y, Hoang T, Sidhu R, Cunningham D. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Sep 25. pii: S1470-2045(17)30566-1. doi: 10.1016/S1470-2045(17)30566-1. [Epub ahead of print]

Kripp M, Prasnikar N, Vehling-Kaiser U, Quidde J, Al-Batran SE, Stein A, Neben K, Hannig CV, Tessen HW, Trarbach T, Hinke A, Hofheinz RD. AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer. Oncotarget. 2017 Sep 23;8(62):105061-105071. doi: 10.18632/oncotarget.21249. eCollection 2017 Dec 1.

Fuchs CS, Muro K, Tomasek J, Van Cutsem E, Cho JY, Oh SC, Safran H, Bodoky G, Chau I, Shimada Y, Al-Batran SE, Passalacqua R, Ohtsu A, Emig M, Ferry D, Chandrawansa K, Hsu Y, Sashegyi A, Liepa AM, Wilke H. Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. J Gastric Cancer. 2017 Jun;17(2):132-144. doi: 10.5230/jgc.2017.17.e16. Epub 2017 Jun 16

Modest DP, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Moehler M, Westphalen CB, Holch JW, von Einem JC, Held S, Heinemann V; for FIRE-3/AIOKRK0306-investigators. Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306). Eur J Cancer. 2017 Aug 23;84:262-269. doi: 10.1016/j.ejca.2017.07.030. [Epub ahead of print]

Peña-Diaz J, Bregenhorn S, Ghodgaonkar M, Follonier C, Artola-Borán M, Castor D, Lopes M, Sartori AA, Jiricny J. Noncanonical Mismatch Repair as a Source of Genomic Instability in Human Cells. Mol Cell. 2017 Jul 6;67(1):162. doi: 10.1016/j.molcel.2017.06.026.

Kim TY, Yen CJ, Al-Batran SE, Ferry D, Gao L, Hsu Y, Cheng R, Orlando M, Ohtsu A. Exposure-response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer. 2017 Jun 20. doi: 10.1007/s10120-017-0737-2. [Epub ahead of print]

Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, Schmalenberg H, Luley KB, Prasnikar N, Egger M, Probst S, Messmann H, Moehler M, Fischbach W, Hartmann JT, Mayer F, Höffkes HG, Koenigsmann M, Arnold D, Kraus TW, Grimm K, Berkhoff S, Post S, Jäger E, Bechstein W, Ronellenfitsch U, Mönig S, Hofheinz RD. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. JAMA Oncol. 2017 Apr 27. doi: 10.1001/jamaoncol.2017.0515. [Epub ahead of print]

Herr UM, Strecker P, Storck SE, Thomas C, Rabiej V, Junker A, Schilling S, Schmidt N, Dowds CM, Eggert S, Pietrzik CU, Kins S. LRP1 Modulates APP Intraneuronal Transport and Processing in Its Monomeric and Dimeric State. Front Mol Neurosci. 2017 Apr 27;10:118. doi: 10.3389/fnmol.2017.00118. eCollection 2017.

Stintzing S, Miller-Phillips L, Modest DP, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Moehler M, Jagenburg A, Kirchner T, Jung A, Heinemann V; FIRE-3 Investigators. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. Eur J Cancer. 2017 Apr 29;79:50-60. doi: 10.1016/j.ejca.2017.03.023. [Epub ahead of print]

Al-Batran SE, Lorenzen S. Management of Locally Advanced Gastroesophageal Cancer: Still a Multidisciplinary Global Challenge? Hematol Oncol Clin North Am. 2017 Jun;31(3):441-452. doi: 10.1016/j.hoc.2017.01.004. Epub 2017 Mar 29.

zur Hausen G, Gröne J, Kaufmann D, Niehues SM, Aschenbrenner K, Stroux A, Hamm B, Kreis ME, Lauscher JC. Influence of pelvic volume on surgical outcome after low anterior resection for rectal cancer. Int J Colorectal Dis. 2017 Mar 18. doi: 10.1007/s00384-017-2793-9. [Epub ahead of print]

Joensuu H, Wardelmann E, Sihto H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Cameron S, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Nilsson B, Kallio R, Junnila J, Vehtari A, Reichardt P. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial. JAMA Oncol.  2017 Mar 23. doi: 10.1001/jamaoncol.2016.5751. [Epub ahead of print]

Lordick F, Al-Batran SE, Dietel M, Gaiser T, Hofheinz RD, Kirchner T, Kreipe HH, Lorenzen S, Möhler M, Quaas A, Röcken C, Rüschoff J, Tannapfel A, Thuss-Patience P, Baretton G. HER2 testing in gastric cancer: results of a German expert meeting. J Cancer Res Clin Oncol. 2017 Mar 11. doi: 10.1007/s00432-017-2374-x. [Epub ahead of print] Review.

Modest DP, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Kirchner T, Jung A, Stauch M, von Einem JC, Moehler M, Held S, Heinemann V; for FIRE-3 study investigators. Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306). Int J Cancer. Int J Cancer. 2017 Apr 15;140(8):1918-1925. doi: 10.1002/ijc.30592.

Sambandan S, Akbalik G, Kochen L, Rinne J, Kahlstatt J, Glock C, Tushev G, Alvarez-Castelao B, Heckel A, Schuman EM.Activity-dependent spatially localized miRNA maturation in neuronal dendrites.Science. 2017 Feb 10;355(6325):634-637. doi: 10.1126/science.aaf8995.

Harbeck N, Saupe S, Jäger E, Schmidt M, Kreienberg R, Müller L, Otremba BJ, Waldenmaier D, Dorn J, Warm M, Scholz M, Untch M, de Wit M, Barinoff J, Lück HJ, Harter P, Augustin D, Harnett P, Beckmann MW, Al-Batran SE; PELICAN Investigators .A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. Breast Cancer Res Treat. 2017 Jan;161(1):63-72. doi: 10.1007/s10549-016-4033-3.

Waberer L, Henrich E, Peetz O, Morgner N, Dötsch V, Bernhard F, Volknandt W. The synaptic vesicle protein SV31 assembles into a dimer and transports Zn2. J Neurochem. 2017 Jan;140(2):280-293. doi: 10.1111/jnc.13886. Epub 2016 Dec 5.

2016

Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016 Oct 21. pii: S1470-2045(16)30531-9. doi: 10.1016/S1470-2045(16)30531-9.

Lee LD, zur Hausen G, Aschenbrenner K, Stroux A, Kreis ME, Lauscher JC. Perioperative platelet inhibition in elective inguinal hernia surgery – increased rate of postoperative bleeding and hematomas? Int Surg In-Press. doi: 10.9738/INTSURG-D-16-00041.1

Quidde J, Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Lange T, Dietrich G, Stoehlmacher J, Reinacher A, Tannapfel A, Trarbach T, Marschner N, Schmoll HJ, Hinke A, Al-Batran SE, Arnold D. Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial. Ann Oncol. 2016 Oct 17. pii: mdw425.

Hofheinz RD, Lange C, Ecke T, Kloss S, Linsse B, Windemuth-Kieselbach C, Hammerer P, Al-BatranSE. Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional QoLiTime study. BJU Int. 2016 Sep 12 doi: 10.1111/bju.13658. [Epub ahead of print]

Hanus C, Geptin H, Tushev G, Garg S, Alvarez-Castelao B, Sambandan S, Kochen L, Hafner AS, Langer JD, Schuman EM1.Unconventional secretory processing diversifies neuronal ion channel properties.Elife. 2016 Sep 28;5. pii: e20609. doi: 10.7554/eLife.20609.

Moehler M, Gepfner-Tuma I, Maderer A, Thuss-Patience PC, Ruessel J, Hegewisch-Becker S, Wilke H, Al-Batran SE, Rafiyan MR, Weißinger F, Schmoll HJ, Kullmann F, von Weikersthal LF, Siveke JT, Weusmann J, Kanzler S, Schimanski CC, Otte M, Schollenberger L, Koenig J, Galle PR. Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. BMC Cancer. 2016 Aug 31;16:699. doi: 10.1186/s12885-016-2736-9.

Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Giessen-Jung C, Moehler M, Jagenburg A, Kirchner T, Jung A, Heinemann. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol. 2016 Aug 27. pii: S1470-2045(16)30269-8. doi: 10.1016/S1470-2045(16)30269-8. [Epub ahead of print]

Lordick F, Al-Batran SE, Hofheinz RD, Lorenzen S, Thuss-Patience P, Baretton GB, Dietel M, Gaiser T, Kirchner T, Kreipe HH, Quaas A, Röcken C, Rüschoff J, Tannapfel A. [HER2 testing in gastric cancer – results of a German expert meeting]. Z Gastroenterol. 2016 Aug;54(8):791-6. doi: 10.1055/s-0042-110794. Epub 2016 Aug 16. German.

Haense N, Atmaca A, Pauligk C, Steinmetz K, Marmé F, Haag GM, Rieger M, Ottmann OG, Ruf P, Lindhofer H, Al-Batran SE. A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors. BMC Cancer. 2016 Jul 7;16:420. doi: 10.1186/s12885-016-2449-0.

Baretton G, Dietel M, Gaiser T, Kirchner T, Kreipe HH, Quaas A, Röcken C, Rüschoff J, Tannapfel A, Lordick F, Al-Batran S, Hofheinz R,Lorenzen S, Moehler M, Thuss-Patience P. HER2 testing in gastric cancer : Results of a meeting of German experts. Pathologe. 2016 Jul;37(4):361-6. doi: 10.1007/s00292-016-0179-3.

Schuldt G, Galanis C, Strehl A, Hick M, Schiener S, Lenz M, Deller T, Maggio N, Vlachos A. Inhibition of Protease-Activated Receptor 1 Does not Affect Dendritic Homeostasis of Cultured Mouse Dentate Granule Cells.Front Neuroanat. 2016 Jun 13;10:64. doi: 10.3389/fnana.2016.00064. eCollection 2016.

Michl M, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmueller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Mueller S, Lerch MM, Modest DP, Kirchner T, Jung A, Heinemann V; FIRE-3 Study Group. CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). Ann Oncol. 2016 May 27. pii: mdw222. [Epub ahead of print]

Lachaud C, Slean M, Marchesi F, Lock C, Odell E, Castor D, Toth R, Rouse J. Karyomegalic interstitial nephritis and DNA damage-induced polyploidy in Fan1 nuclease-defective knock-in mice. Genes Dev. 2016 Mar 15;30(6):639-44. doi: 10.1101/gad.276287.115.

Reuschenbach M, Pauligk C, Karbach J, Rafiyan MR, Kloor M, Prigge ES, Sauer M, Al-Batran SE, Kaufmann AM, Schneider A,Jäger E, von Knebel Doeberitz M. A phase 1/2a study to test the safety and immunogenicity of a p16INK4a peptide vaccine in patients with advanced human papillomavirus-associated cancers. Cancer. 2016 Mar 7. doi: 10.1002/cncr.29925. [Epub ahead of print]

Müller DW, Pauligk C, Al-Batran S-E. Potenzial chirurgischer Interventionen – Resektion von Primärtumor und/oder Metastasen bei metastasierten Adenokarzinomen des Magens oder des ösophagogastralen Übergangs. CONNEXI. Nr 1, 4 Jahrgang, Februar 2016.

Kaufmann D, Lauscher JC, Gröne J, zur Hausen G, Kreis ME, Hamm B, Niehues SM. CT-based measurement of the inner pelvic volume. Acta Radiologica. 2016 Mar 9. doi:10.1177/0284185116637248

Al-Batran SE, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov ON, Kim TY, Cunningham D, Rougier P, Muro K, Liepa AM, Chandrawansa K, Emig M, Ohtsu A, Wilke H. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma†. Ann Oncol. 2016 Jan 7. pii: mdv625. [Epub ahead of print]

2015

Müller DW, Mönig S, Lorenz D, Homann N, Rödel C, Shah MA, Sasako M, Zander T, Pauligk C, Al-Batran S-E. Renaissance / FLOT5 – Effekt von Chemotherapie alleine vs. Chemotherapie gefolgt von operative Resektion auf Überleben und Lebensqualität bei Patienten mit limitiert-metastasierten Adenokarzinomen des Magens oder des ösophagogastralen Übergangs – eine Phase III Studie der AIO/CAO-V/CAOGI. FORUM. 2015. 30:536-537.

Goetze TO. Gallbladder carcinoma: Prognostic factors and therapeutic options World J Gastroenterol 21(43):12211-12217. Published online 2015 November 21.doi: 10.3748/wjg.v21.i43.12211.

Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Ramadori G, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Nilsson B, Sihto H, Bono P, Kallio R, Junnila J, Alvegård T, Reichardt P. Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. J Clin Oncol. 2015 Nov 2. pii: JCO.2015.62.9170. [Epub ahead of print]

Vogel A, Kullmann F, Kunzmann V, Al-Batran SE, Oettle H, Plentz R, Siveke J, Springfeld C, Riess H. Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine. Oncol Res Treat. 2015;38(11):596-603. doi: 10.1159/000441310. Epub 2015 Oct 20.

Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2015 Oct;16(13):1355-69. doi: 10.1016/S1470-2045(15)00042-X. Epub 2015 Sep 8.

Modest DP, Stintzing S, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G,Kullmann F, Stauch M, Scheithauer W, Held S, Möhler M, Jung A, Kirchner T, Heinemann V. Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer. J Clin Oncol. 2015 Aug 10. pii: JCO.2015.61.2887. [Epub ahead of print]

Kripp M, Al-Batran SE, Hofheinz RD. Gastric Cancer. 2016 Jan;19(1):320-1. doi: 10.1007/s10120-015-0532-x. Epub 2015 Aug 20

Hofheinz RD, Gencer D, Schulz H, Stahl M, Hegewisch-Becker S, Loeffler LM, Kronawitter U, Bolz G, Potenberg J, Tauchert F, Al-Batran SE, Schneeweiss A. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group. J Clin Oncol. 2015 Aug 1;33(22):2444-9. doi: 10.1200/JCO.2014.60.4587. Epub 2015 Jun 29

Schulz C, Kullmann F, Kunzmann V, Fuchs M, Geissler M, Vehling-Kaiser U, Stauder H, Wein A, Al-Batran SE, Kubin T, Schäfer C, Stintzing S, Giessen C, Modest DP, Ridwelski K, Heinemann V. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. Int J Cancer. 2015 Aug 1;137(3):678-85. doi: 10.1002/ijc.29403. Epub 2015 Feb 25

Gentili C, Castor D, Kaden S, Lauterbach D, Gysi M, Steigemann P, Gerlich DW, Jiricny J, Ferrari S. PLoS One. 2015 Jul 22;10(7):e0133576. doi: 10.1371/journal.pone.0133576. eCollection 2015. Chromosome Missegregation Associated with RUVBL1 Deficiency.

Al-Batran SE, Hozaeel W, Tauchert FK, Hofheinz RD, Hinke A, Windemuth-Kieselbach C, Hübner A, Burmester M, Koenigsmann M, Wiegand J, Zur Hausen G, Linsse B, Kuhl R, Pauligk C; Arbeitsgemeinschaft Internistische Onkologie (AIO). The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax). Ann Oncol. 2015 Jun;26(6):1244-8. doi: 10.1093/annonc/mdv129. Epub 2015 Mar 9.

Atmaca A, Wirtz RW, Werner D, Steinmetz K, Claas S, Brueckl WM, Jäger E, Al-Batran SE. SNAI2/SLUG and estrogen receptor mRNA expression are inversely correlated and prognostic of patient outcome in metastatic non-small cell lung cancer.  BMC Cancer. 2015 Apr 17;15:300. doi: 10.1186/s12885-015-1310-1

Deckmann K, Krasteva-Christ G, Rafiq A, Herden C, Wichmann J, Knauf S, Nassenstein C, Grevelding CG, Dorresteijn A, Chubanov V, Gudermann T, Bschleipfer T, Kummer W. Cholinergic urethral brush cells are widespread throughout placental mammals. Int Immunopharmacol. 2015;29(1):51-6.

Damijonaitis A, Broichhagen J, Urushima T, Hüll K, Nagpal J, Laprell L, Schönberger M, Woodmansee DH, Rafiq A, Sumser MP, Kummer W, Gottschalk A, Trauner D. AzoCholine enables optical control of alpha 7 nicotinic acetylcholine receptors in neural networks. ACS Chem Neurosci. 2015;6(5):701-7.

Fijak M, Damm LJ, Wenzel JP, Aslani F, Walecki M, Wahle E, Eisel F, Bhushan S, Hackstein H, Baal N, Schuler G, Konrad L, Rafiq A, O’Hara L, Smith LB, Meinhardt A. Influence of testosterone on inflammatory response in testicular cells and expression of transcription factor foxp3 in T Cells. Am J Reprod Immunol. 2015;74(1):12-25.

Hipp M, Pilz L, Al-Batran SE, Hautmann MG, Hofheinz RD. Workload and Quality of Life of Medical Doctors in the Field of Oncology in Germany – a Survey of the Working Group Quality of Life of the AIO for the Study Group of Internal Oncology. Oncol Res Treat. 2015;38(4):154-9. doi: 10.1159/000381074. Epub 2015 Mar 31.

Tom Dieck S, Kochen L, Hanus C, Heumüller M, Bartnik I, Nassim-Assir B, Merk K, Mosler T, Garg S, Bunse S, Tirrell DA, Schuman EM.Direct visualization of newly synthesized target proteins in situ.Nat Methods. 2015 May;12(5):411-4. doi: 10.1038/nmeth.3319. Epub 2015 Mar 16.

Amato G, Romano G, Agrusa A, Marasa S, Cocorullo G, Gulotta G, Goetze T, Puleio R. Biologic response of inguinal hernia prosthetics: a comparative study of conventional static meshes versus 3D dynamic implants. Artif Organs. 2015 Jan;39(1):E10-23. doi: 0.1111/aor.12416.

2014

Goetze TO, Paolucci V. Influence of high- and low-volume liver surgery in gallbladder carcinoma. World J Gastroenterol. 2014 Dec 28;20(48):18445-51. doi: 0.3748/wjg.v20.i48.18445.

Schulz C, Kullmann F, Kunzmann V, Fuchs M, Geissler M, Vehling-Kaiser U, Stauder H, Wein A, Al-Batran SE, Kubin T, Schäfer C, Stintzing S, Giessen C, Modest DP, Ridwelski K, Heinemann V. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. Int J Cancer. 2014 Dec 22. doi: 10.1002/ijc.29403. [Epub ahead of print]

Nair N, Castor D, Macartney T, Rouse J. DNA Repair (Amst). Identification and characterization of MUS81 point mutations that abolish interaction with the SLX4 scaffold protein. 2014 Dec;24:131-137. doi: 10.1016/j.dnarep.2014.08.004. Epub 2014 Sep 16.

Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Ballman KV, Leinonen M, Dematteo RP, Reichardt P. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer. 2014 Aug 1;120(15):2325-33.

Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Jul 31. pii: S1470-2045(14)70330-4. doi: 10.1016/S1470-2045(14)70330-4. [Epub ahead of print]

Becker D, Ikenberg B, Schiener S, Maggio N, Vlachos A. NMDA-receptor inhibition restores Protease-Activated Receptor 1 (PAR1) mediated alterations in homeostatic synaptic plasticity of denervated mouse dentate granule cells. Neuropharmacology. 2014 Nov;86:212-8. doi: 0.1016/j.neuropharm.2014.07.013. Epub 2014 Jul 30.

Pfeil U, Kuncova J, Brüggmann D, Paddenberg R, Rafiq A, Henrich M, Weigand MA, Schlüter KD, Mewe M, Middendorff R, Slavikova J, Kummer W. Intrinsic vascular dopamine – a key modulator of hypoxia-induced vasodilatation in splanchnic vessels. J Physiol. 2014; 592(Pt 8):1745-56.

Deckmann K, Filipski K, Krasteva-Christ G, Fronius M, Althaus M, Rafiq A, Papadakis T, Renno L, Jurastow I, Wessels L, Wolff M, Schütz B, Weihe E, Chubanov V, Gudermann T, Klein J, Bschleipfer T, Kummer W. Bitter triggers acetylcholine release from polymodal urethral chemosensory cells and bladder reflexes. Proc Natl Acad Sci U S A. 2014; 111(22):8287-92.

Panneck AR, Rafiq A, Schütz B, Soultanova A, Deckmann K, Chubanov V, Gudermann T, Weihe E, Krasteva-Christ G, Grau V, del Rey A, Kummer W. Cholinergic epithelial cell with chemosensory traits in murine thymic medulla. Cell Tissue Res. 2014; 358(3):737-48. doi: 10.1007/s00441-014-2002-x.

Soultanova A, Panneck AR, Rafiq A, Kummer W. Terminally differentiated epithelial cells of the thymic medulla and skin express nicotinic acetylcholine receptor subunit α 3. Biomed Res Int. 2014; 2014:757502.

Thomaidis T, Maderer A, Al-Batran SE, Kany J, Pauligk C, Steinmetz K, Schad A, Hofheinz R, Schmalenberg H, Homann N, Galle PR, Moehler M.VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).BMC Cancer. 2014 Jul 1;14:476. doi: 10.1186/1471-2407-14-476.

Bilgin M, Burgazli KM, Rafiq A, Mericliler M, Neuhof C, Oliva ML, Parahuleva M, Soydan N, Doerr O, Abdallah Y, Erdogan A. Effect of Bauhinia bauhinioides kallikrein inhibitor on endothelial proliferation and intracellular calcium concentration. Eur Rev Med Pharmacol Sci. 2014; 18(1):46-51.

Al-Batran SE, Werner D. Recent advances and future trends in the targeted therapy of metastatic gastric cancer. Expert Rev Gastroenterol Hepatol. 2014 Jul;8(5):555-69.

Werner D*, Battmann A*, Steinmetz K, Jones T, Lamb T, Martinez M, Altmannsberger HM, Al-Batran SE. The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing. Journal of Translational Medicine. (*both authors contributed equally to this study). J Transl Med. 2014 Jun 6;12:160.

Hanus C, Kochen L, Tom Dieck S, Racine V, Sibarita JB, Schuman EM, Ehlers MD.Synaptic control of secretory trafficking in dendrites.Cell Rep. 2014 Jun 26;7(6):1771-8. doi: 10.1016/j.celrep.2014.05.028. Epub 2014 Jun 12.

Lachaud C, Castor D, Hain K, Muñoz I, Wilson J, MacArtney TJ, Schindler D, Rouse J. Distinct functional roles for the two SLX4 ubiquitin-binding UBZ domains mutated in Fanconi anemia.  J Cell Sci. 2014 Jul 1;127(Pt 13):2811-7. doi: 10.1242/jcs.146167. Epub 2014 May 2.

Amato G, Romano G, Agrusa A, Cocorullo G, Gulotta G, Goetze T. Dynamic inguinal hernia repair with a 3d fixation-free and motion-compliant implant: a clinical study. Surg Technol Int. 2014 Mar;24:155-65.

Al-Batran SE. The role of radiation therapy for resectable adenocarcinoma of the gastroesophageal junction. Oncologist. 2014;19(4):431. doi: 10.1634/theoncologist.2013-0424.

Al-Batran SE, Geissler M, Seufferlein T, Oettle H. Nab-Paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action. Oncol Res Treat. 2014;37(3):128-34. doi: 10.1159/000358890. Epub 2014 Feb 7.

Goetze TO, Paolucci V. Extended cholecystectomy an underestimated prognostic factor in T1b- T3 incidental gallbladder carcinoma- Results of the German- Registry Chirurg. 2014 Feb;85(2):131-8. doi: 10.1007/s00104-013-2587-8.

Kripp M, Al-Batran SE, Rosowski J, Pauligk C, Homann N, Hartmann JT, Moehler M, Hofheinz RD. Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Gastric Cancer. 2014 Jan;17(1):181-7.

Miranda MB, Hartmann JT, Al-Batran SE, Kripp M, Gencer D, Hochhaus A, Hofheinz RD, Merx K. Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study. J Cancer Res Clin Oncol. 2014 Feb 21.

Atmaca A, Al-Batran SE, Wirtz RM, Werner D, Zirlik S, Wiest G, Eschbach C, Claas S, Hartmann A, Ficker JH, Jäger E, Brueckl WM. The validation of estrogen receptor 1 (ESR1) mRNA expression as a predictor of outcome in patients with metastatic non-small cell lung cancer. Int J Cancer. 2014 May 15;134(10):2314-21.

2013

Will TJ, Tushev G, Kochen L, Nassim-Assir B, Cajigas IJ, Tom Dieck S, Schuman EM. Deep sequencing and high-resolution imaging reveal compartment-specific localization of Bdnf mRNA in hippocampal neurons. Sci Signal. 2013 Dec 17;6(306):rs16. doi: 10.1126/scisignal.2004520.

Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D, Van Cutsem E.Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study. J Clin Oncol. 2013 Nov 1;31(31):3935-43.

Stenholm L, Stoehlmacher-Williams J, Al-Batran SE, Heussen N, Akin S, Pauligk C, Lehmann S, Senff T, Hofheinz RD, Ehninger G, Kramer M, Goekkurt E. Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Ann Oncol. 2013 Oct;24(10):2581-8.

Aslam M, Schluter KD, Rohrbach S, Rafiq A, Nazli S, Piper HM, Noll T, Schulz R, Gündüz D. Hypoxia-reoxygenation-induced endothelial barrier failure: role of RhoA, Rac1 and myosin light chain kinase. J Physiol. 2013; 591(Pt 2):461-73.

Brueckl WM, Al-Batran SE, Ficker JH, Claas S, Atmaca A, Hartmann A, Rieker RJ, Wirtz RM. Prognostic and predictive value of estrogen receptor 1 expression in completely resected non-small cell lung cancer. Int J Cancer. 2013 Oct 15;133(8):1825-31.

Gutt, Carsten N. MD; Encke, Jens MD; Köninger, Jörg MD; Harnoss, Julian-Camill MD; Weigand, Kilian MD; Kipfmüller, Karl MD; Schunter, Oliver MD; Götze, Thorsten MD Golling, Markus T. MD; Menges, Markus MD; Klar, Ernst MD; Feilhauer, Katharina MD; Zoller, Wolfram G. MD; Ridwelski, Karsten MD; Ackmann, Sven MD; Baron, Alexandra MD; Schön, Michael R. MD; Seitz, Helmut K. MD; Daniel, Dietmar MSc; Stremmel, Wolfgang MD; Büchler, Markus W. MD, Acute Cholecystitis: Early Versus Delayed Cholecystectomy, A Multicenter Randomized Trial (ACDC Study, NCT00447304) Ann Surg September 2013 – Volume 258 – Issue 3 – p 385–393 doi: 10.1097/SLA.0b013e3182a1599b

Castor D, Nair N, Déclais AC, Lachaud C, Toth R, Macartney TJ, Lilley DM, Arthur JS, Rouse J. Cooperative control of holliday junction resolution and DNA repair by the SLX1 and MUS81-EME1 nucleases. Mol Cell. 2013 Oct 24;52(2):221-33. doi: 0.1016/j.molcel.2013.08.036. Epub 2013 Sep 26.

de Marinis F, Atmaca A, Tiseo M, Giuffreda L, Rossi A, Gebbia V, Antonio CD, Zotto LD, Al-Batran SE, Marsoni S, Wolf M. A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer. J Thorac Oncol. 2013 Aug;8(8):1091-1094.

Wilson JS, Tejera AM, Castor D, Toth R, Blasco MA, Rouse J. Localization-dependent and -independent roles of SLX4 in regulating telomeres. Cell Rep. 2013 Sep 12;4(5):853-60. doi: 10.1016/j.celrep.2013.07.033. Epub 2013 Aug 29.

Lorenzen S, Thuss-Patience P, Al-Batran SE, Lordick F, Haller B, Schuster T, Pauligk C, Luley K, Bichev D, Schumacher G, Homann N. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Ann Oncol. 2013 Aug;24(8):2068-73.

Goetze TO, Paolucci V. Prognosis of incidental gallbladder carcinoma is not influenced by the primary access technique: analysis of 837 incidental gallbladder carcinomas in the German Registry. Surg Endosc. 2013 Aug;27(8):2821-8. Epub 2013 Feb 13.

Werner D*, Atmaca A*, Pauligk C, Pustowka A, Jäger E, Al-Batran SE. Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma. Cancer Med. 2013 Jun;2(3):325-33. (*both authors contributed equally to this study).

Bankstahl US, Görtelmeyer R. Measuring subjective complaints of attention and performance failures–development and psychometric validation in tinnitus of the self-assessment scale APSA. Health Qual Life Outcomes. 2013 May 29;11:86. doi: 10.1186/1477-7525-11-86

Kamil Burgazli M, Aydogdu N, Rafiq A, Mericliler M, Chasan R, Erdogan A. Effects of caffeic acid phenethyl ester (CAPE) on membrane potential and intracellular calcium in human endothelial cells. Eur Rev Med Pharmacol Sci. 2013; 17(6):720-8.

Limm K, Ott C, Wallner S, Mueller DW, Oefner P, Hellerbrand C, Bosserhoff AK. Deregulation of protein methylation in melanoma Eur J Cancer. 2013 Apr;49(6):1305-13. Epub 2012 Dec 19.

Al-Batran S-E, Pauligk C, Homann N, Hartmann JT, Moehler M, Probst S, Rethwisch V, Stoehlmacher-Williams J, Prasnikar N, Hollerbach S, Bokemeyer C, Mahlberg R, Hofheinz RD, Luley K, Kullmann F, Jäger E. The Feasibility of Triple-Drug Chemotherapy Combination in Older Adult Patients with Esophagogastric Cancer: a Randomized Trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). Eur J Cancer. 2013 Mar;49(4):835-42.

Atmaca A, Al-Batran SE, Werner D, Pauligk C, Güner T, Koepke A, Bernhard H, Wenzel T, Banat AG, Brueck P, Caca K, Prasnikar N, Kullmann F, Günther Derigs H, Koenigsmann M, Dingeldein G, Neuhaus T, Jäger E. A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer. Br J Cancer. 2013 Feb 5;108(2):265-70.

Gencer D, Al-Batran SE, Dada R, Hünerlitürkoglu AN, Gonnermann M, Kegel T, Scheiber H, Jordan WO, Burkholder I, Kellermann L, Hofheinz RD. Metastatic esophagogastric adenocarcinoma: trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval. J Cancer Res Clin Oncol. 2013 Feb;139(2):337-45.

Lorenzen S, Pauligk C, Homann N, Schmalenberg H, Jäger E, Al-Batran SE. Feasibility of perioperative Chemotherapy with infusional 5-FU, Leucovorin and Oxaliplatin with or without Docetaxel in elderly patients with locally advanced esophagogastric cancer. Br J Cancer. 2013 Feb 19;108(3):519-26.

2012

Peña-Diaz J1, Bregenhorn S, Ghodgaonkar M, Follonier C, Artola-Borán M, Castor D, Lopes M, Sartori AA. Jiricny JNoncanonical mismatch repair as a source of genomic instability in human cells. Mol Cell. 2012 Sep 14;47(5):669-80. doi: 10.1016/j.molcel.2012.07.006. Epub 2012 Aug 2.

Atmaca A, Werner D, Pauligk C, Steinmetz K, Wirtz R, Altmannsberger HM, Jäger E, Al-Batran SE. The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer. BMC Cancer. 2012 Nov 15;12:524.

Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, Shah MA, Al-Batran SE. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012 Oct;23(10):2656-62.

Wimberger P, Gilet H, Gonschior AK, Heiss MM, Moehler M, Oskay-Oezcelik G, Al-Batran SE, Schmalfeldt B, Schmittel A, Schulze E, Parsons SL. Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Ann Oncol. 2012 Aug;23(8):1979-85.

Al-Batran SE, Pauligk C, Wirtz R, Werner D, Steinmetz K, Homann N, Schmalenberg H, Hofheinz RD, Hartmann JT, Atmaca A, Altmannsberger HM, Jäger E. The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer. Ann Oncol. 2012 Jul;23(7):1699-705.

Al-Batran SE, Hozaeel W, Jäger E. Combination of trastuzumab and triple FLOT chemotherapy (5-fluorouracil/leucovorin, oxaliplatin, and docetaxel) in patients with HER2-positive metastatic gastric cancer: report of 3 cases. Onkologie. 2012;35(9):505-8.

Goetze TO, Paolucci V. The prognostic impact of positive lymph nodes in stages T1 to T3 incidental gallbladder carcinoma: results of the German Registry Surg Endosc. 2012 May;26(5):1382-9. Epub 2011 Nov 17

Homann N, Pauligk C, Luley K, Werner Kraus T, Bruch HP, Atmaca A, Noack F, Altmannsberger HM, Jäger E, Al-Batran SE. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. Int J Cancer.  2012 Apr 1;130(7):1706-13.

Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012 Mar 28;307(12):1265-72.

Brachner A1, Braun J, Ghodgaonkar M, Castor D, Zlopasa L, Ehrlich V, Jiricny J, Gotzmann J, Knasmüller S, Foisner R. The endonuclease Ankle1 requires its LEM and GIY-YIG motifs for DNA cleavage in vivo. J Cell Sci. 2012 Feb 15;125(Pt 4):1048-57. doi: 10.1242/jcs.098392. Epub 2012 Mar 7.

Al-Batran SE, Ducreux M, Ohtsu A. mTOR as a therapeutic target in patients with gastric cancer. Int J Cancer. 2012 Feb;130(3):491-6.

Bankstahl US, Elkin EP, Gebauer A, Görtelmeyer R. Validation of the THI-12 questionnaire for international use in assessing tinnitus: a multi-centre, prospective, observational study. Int J Audiol. 2012 Sep;51(9):671-7. doi: 10.3109/14992027.2011.653448. Epub 2012 Feb 20.

Aslam M, Pfeil U, Gündüz D, Rafiq A, Kummer W, Piper HM, Noll T. Intermedin (adrenomedullin2) stabilizes the endothelial barrier and antagonizes thrombin-induced barrier failure in endothelial cell monolayers. Br J Pharmacol. 2012; 165(1):208-22.

2011

Atmaca A, Pauligk C, Steinmetz K, Altmannsberger HM, Jäger E, Al-Batran SE. Prognostic impact of phosphorylated mitogen-activated protein kinase expression in patients with metastatic gastric cancer. Oncology. 2011;80(1-2):130-4.

Mueller DW, Bosserhoff AK. miRNAs as biomarkers and therapeutic targets in malignant melanoma. In: Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma (Current Clinical Pathology). Editor: Michael Murphy. Humana Press Inc., Springer Science+Business Media. 2011. Buchkapitel.

Gencer D, Tauchert F, Keilhauer N, Al-Batran SE, Stahl M, Oskay-Özcelik G, Hipp M, Leibbrand B, Prasnikar N, Trarbach T, Stoll C, van Kampen M, Hochhaus A, Lorenzen S, Hofheinz RD. Cancer Patients and the Internet: A Survey of the ‘Quality of Life’ Working Groups of the Arbeitsgemeinschaft für Internistische Onkologie and the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie. Onkologie. 2011;34(8-9):435-40.

Eichbaum M, Mayer C, Eickhoff R, Bischofs E, Gebauer G, Fehm T, Lenz F, Fricke HC, Solomayer E, Fersis N, Schmidt M, Wallwiener M, Schneeweiss A, Sohn C. The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. BMC Cancer. 2011 Oct 20;11:453. doi: 10.1186/1471-2407-11-453.

Weidmann E, Neumann A, Fauth F, Atmaca A, Al-Batran SE, Pauligk C, Jäger E. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol. 2011 Aug;22(8):1839-44.

Moehler M, Mueller A, Hartmann JT, Ebert MP, Al-Batran SE, Reimer P, Weihrauch M, Lordick F, Trarbach T, Biesterfeld S, Kabisch M, Wachtlin D, Galle PR; German Arbeitsgemeinschaft Internistische Onkologie (AIO). An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer. 2011 Jul;47:1511-20.

G. Amato , G. Romano , T. Goetze , G. Salamone , A. Agrusa , G. Gulotta, V. Paolucci New mesh shape and improved implantation procedure to simplify and standardize open ventral hernia repair: a preliminary report Hernia 2011 15(6):659-65

Moehler M, Al-Batran SE, Andus T et al. German S3-guideline “Diagnosis and treatment of esophagogastric cancer”. Z Gastroenterol. 2011 Apr;49(4):461-531.

Goetze TO, Paolucci V. Immediate Radical Re-Resection of Incidental T1b Gallbladder Cancer and the Problem of an Adequate Extent of Resection (Results of the German Registry “Incidental Gallbladder Cancer” Zentralbl Chir. 2011 Mar 1

Vettermann C1, Castor D, Mekker A, Gerrits B, Karas M, Jäck HM. Proteome profiling suggests a pro-inflammatory role for plasma cells through release of high-mobility group box 1 protein. Proteomics. 2011 Apr;11(7):1228-37. doi: 10.1002/pmic.201000491. Epub 2011 Feb 14.

Mueller DW, Bosserhoff AK. MicroRNA miR-196a controls melanoma-associated genes by regulating HOX-C8 expression. Int J Cancer. 2011 Sep 1;129(5):1064-74. Epub 2011 Feb 11.

Mueller DW, Bosserhoff AK. MicroRNAs in malignant melanoma. In: Melanoma Development: Molecular Biology, Genetics and Clinical Application. Editor: Anja Bosserhoff. Springer Verlag, Wien. 2011. Buchkapitel.

Karbach J, Neumann A, Atmaca A, Wahle C, Brand K, von Boehmer L, Knuth A, Bender A, Ritter G, Old LJ, Jäger E. Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. Clin Cancer Res. 2011 Feb 15;17(4):861-70.

Al-Batran SE, Ruppert M, Jäger E. Trastuzumab plus chemotherapy in gastric cancer overexpressing HER-2 and EGFR: a case report. Onkologie. 2011;34(1-2):42-5.

2010

Al-Batran SE, Güntner M, Pauligk C, Scholz M, Chen R, Beiss B, Stopatschinskaja S, Lerbs W, Harbeck N, Jäger E.  Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials. Br J Cancer. 2010 Nov 9;103(10):1518-23.

A.T. Henze, J. Riedel, T. Diem, J. Wenner, I. Flamme, J. Pouyseggur, K.H. Plate, T. Acker (2010) „Prolyl hydroxylases 2 and 3 act in gliomas as protective negative feedback regulators of hypoxia-inducible factors”, Cancer Research, 70(1): 357-66

Hofheinz RD*, Al-Batran SE*, Hochhaus A, Jäger E, Reichardt VL, Fritsch H, Trommeshauser D, Munzert G. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res. 2010 Sep 15;16(18):4666-74. (*geteilte Erstautorenschaft)

Goetze TO, Paolucci V. Adequate extent in radical re-resection of incidental gallbladder carcinoma: analysis of the German Registry. Surg Endosc. 2010 Sep;24(9):2156-64.

Goetze TO, Paolucci V. World J Surg. 2010 Sep;34(9):2262-3; author reply 2264-5.

Hofheinz RD, Al-Batran SE, Ridwelski K, Görg C, Wehle K, Birth M, Fetscher S, Scheiber H, Lukan N, Lordick F. Population-based patterns of care in the first-line treatment of patients with advanced esophagogastric adenocarcinoma in Germany. Onkologie. 2010;33(10):512-8.

Hassel JC, Kripp M, Al-Batran S, Hofheinz RD. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists. Onkologie. 2010;33(3):94-8.

Mueller DW, Bosserhoff AK. The evolving concept of “melano-miRs” – microRNAs in melanomagenesis. Pigment Cell Melanoma Res. 2010 Oct;23(5):620-6. Epub 2010 Jul 12.

Braig S*, Mueller DW*, Rothhammer T, Bosserhoff AK. MicroRNA miR-196a is a central regulator of HoxB7 and BMP4 expression in malignant melanoma. Cell Mol Life Sci. 2010 Oct;67(20):3535-48. Epub 2010 May 18. *beide Autoren sind Erstautoren.

Al-Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer. 2010 Jun 1;116(11):2511-8.

Neumann A, Karbach J, Atmaca A, Jäger E. Long-term remission of malignant melanoma stage IV after antigen-specific immunotherapy. Med Klin (Munich). 2010 Apr;105(4):273-5.

2009

Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, Moehler M, Grabowski P, Arnold D, Greten T, Müller L, Röthling N, Peschel C, Langer R, Lordick F. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009 Oct;20(10):1667-73.

Goetze TO, Paolucci V. Use of retrieval bags in incidental gallbladder cancer cases. World J Surg. 2009 Oct;33(10):2161-5.

Müller DW, Meyer C, Gürster S, Küper U, Huber H, Rachel R, Wanner G, Wirth R, Bellack A. The Iho670 fibers of Ignicoccus hospitalis: a new type of archaeal cell surface appendage. J Bacteriol 2009 Oct ;191(20):6465-8. Epub 2009 Aug 14.

Müller DW, Bosserhoff AK. miR(acle)s – new players in the regulation of known suspects. Pigment Cell Melanoma Res2009 Oct;22(5):525-6. Epub 2009 Aug 11. News and Views Artikel.

Mueller DW, Bosserhoff AK. Role of miRNAs in the progression of malignant melanoma. Br J Cancer. 2009 Aug 18;101(4):551-6. Epub 2009 Jul 28. Review.

Wanner RM1, Castor D, Güthlein C, Böttger EC, Springer B, Jiricny J. The uracil DNA glycosylase UdgB of Mycobacterium smegmatis protects the organism from the mutagenic effects of cytosine and adenine deamination. J Bacteriol. 2009 Oct;191(20):6312-9. doi: 10.1128/JB.00613-09. Epub 2009 Aug 14.

Pfeil U, Aslam M, Paddenberg R, Quanz K, Chang CL, Park JI, Gries B, Rafiq A, Faulhammer P, Goldenberg A, Papadakis T, Noll T, Hsu SY, Weissmann N, Kummer W. Intermedin/adrenomedullin-2 is a hypoxia-induced endothelial peptide that stabilizes pulmonary microvascular permeability. Am J Physiol Lung Cell Mol Physiol. 2009; 297(5):L837-45.

Mueller DW, Rehli M, Bosserhoff AK. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol. 2009 Jul;129(7):1740-51. Epub 2009 Feb 12.

Goekkurt E, Al-Batran SE, Hartmann JT, Mogck U, Schuch G, Kramer M, Jaeger E, Bokemeyer C, Ehninger G, Stoehlmacher J. Pharmacogenetic Analyses of a Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2009 Jun 10;27(17):2863-73.

Goekkurt E, Al-Batran SE, Mogck U, Pauligk C, Hartmann JT, Kramer M, Jaeger E, Ehninger G, Stoehlmacher J. Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Ann Oncol. 2009 Mar;20(3):481-5.

Schanz S1, Castor D, Fischer F, Jiricny J. Interference of mismatch and base excision repair during the processing of adjacent U/G mispairs may play a key role in somatic hypermutation. Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5593-8. doi: 10.1073/pnas.0901726106. Epub 2009 Mar 23.

Atmaca A, Al-Batran SE, Neumann A, Kolassa Y, Jäger D, Knuth A, Jäger E. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer – A phase II study. Gynecol Oncol. 2009 Feb;112(2):384-8.

Huebner G, Link H, Kohne CH, Stahl M, Kretzschmar A, Steinbach S, Folprecht G, Bernhard H, Al-Batran SE, Schoffski P, Burkart C, Kullmann F, Otremba B, Menges M, Hoffmann M, Kaiser U, Aldaoud A, Jahn A.Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer. 2009 Jan 13;100(1):44-9.

Filip AM, Klug J, Cayli S, Fröhlich S, Henke T, Lacher P, Eickhoff R, Bulau P, Linder M, Carlsson-Skwirut C, Leng L, Bucala R, Kraemer S, Bernhagen J, Meinhardt A. Ribosomal protein S19 interacts with macrophage migration inhibitory factor and attenuates its pro-inflammatory function. J Biol Chem. 2009 Mar 20;284(12):7977-85. doi: 10.1074/jbc.M808620200. Epub 2009 Jan 20.

Al-Batran SE, Ajani JA. Accomplishments in 2008 in the management of advanced gastroesophageal cancer. Gastrointest Cancer Res. 2009 Sep;3(5 Supplement 2):58-61.

2008

Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, Stoehlmacher J, Clemens MR, Mahlberg R, Fritz M, Seipelt G, Sievert M, Pauligk C, Atmaca A, Jäger E. Biweekly Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT) is Active and has a Favorable Safety Profile for Patients with Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction: a Phase II Trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008 Nov;19(11):1882-7.

Müller DW, Bosserhoff AK. Integrin beta(3) expression is regulated by let-7a miRNA in malignant melanoma. Oncogene. 2008 Nov 6;27(52):6698-706. Epub 2008 Aug 4.

Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: A study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26:1435-1442, 2008.

Burghardt T, Saller M, Gürster S, Müller D, Meyer C, Jahn U, Hochmuth E, Deutzmann R, Siedler F, Babinger P, Wirth R, Huber H, Rachel R. Insight into the proteome of the hyperthermophilic Crenarchaeon Ignicoccus hospitalis: the major cytosolic and membrane proteins. Arch Microbiol. 2008 Sep;190(3):379-94. Epub 2008 Jun 27.

Oskay-Oezcelik G, Koensgen D, Hindenburg HJ, Klare P, Schmalfeldt B, Lichtenegger W, Chekerov R, Al-Batran SE, Neumann U, Sehouli J. Ovarian Cancer Study Group of the North-Eastern Germany Society of Gynecological Oncology (NOGGO). Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO. Anticancer Res. 2008 Mar-Apr;28(2B):1329-34.

Wedel SA, Sparatore A, Del Soldato P, Al-Batran SE, Atmaca A, Juengel E, Hudak L, Jonas D, Blaheta RA. New Histone Deacetylase Inhibitors As Potential Therapeutic Tools For Advanced Prostate Carcinoma. J Cell Mol Med. 2008 Dec;12(6A):2457-66.

Lordick F, Ridwelski K, Al-Batran SE, Trarbach T, Schlag PM, Piso P. Treatment of gastric cancer. Onkologie. 2008;31 Suppl 5:32-9.

Hofheinz RD, Beyer U, Al-Batran SE, Hartmann JT.Mitomycin C in the treatment of gastrointestinal tumours: recent data and perspectives.Onkologie. 2008 May;31(5):271-81.

Goetze TO, Paolucci V. Immediate re-resection of T1 incidental gallbladder carcinomas: a survival analysis of the German Registry. Surg Endosc. 2008 Feb 5;

Goetze TO, Paolucci V. Benefits of reoperation of T2 and more advanced incidental gallbladder carcinoma: analysis of the German registry. Ann Surg. 2008 Jan;247(1):104-8.

2007

Al-Batran SE, Hartmann JT, Heidel F, Stoehlmacher J, Wardelmann E, Dechow C, Düx M, Izbicki JR, Kraus T, Fischer T, Jäger E. Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients. Gastric Cancer. 2007;10(3):145-522006.

Al-Batran SE , Atmaca A , Schleyer E , Pauligk C, Hosius C , Ehninger G , Jäger E. Imatinib Mesylate for Targeting the Platelet-derived Growth Factor Beta-receptor (PDGFR-ß) in Combination with Fluorouracil and Leucovorin in Patients with Refractory Pancreatic, Bile Duct, Colorectal, or Gastric Cancer – a Dose Escalation Phase I Trial. Cancer 2007 May 1;109(9):1897-904.

Al-Batran SE,  Kerber A, Atmaca A, Dechow C, Reitsamer E,  Schmidt S,  Kolassa Y, Neumann A,  Weidmann E, Hartmann JT,  Jäger E. Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial. Onkologie. 2007 Feb;30(1-2):29-34.

Kretzschmar A, Wiege T, Al-Batran SE, Hinrichs HF, Kindler M, Steck T, Illiger HJ, Heinemann V, Schmidt K, Haus U, Kirner A, Ehninger G. Rapid and sustained influence of intravenous zoledronic Acid on course of pain and analgesics consumption in patients with cancer with bone metastases: a multicenter open-label study over 1 year. Support Cancer Ther. 2007 Sep 1;4(4):203-10.

Bender A, Karbach J, Neumann A, Jäger D, Al-Batran SE, Atmaca A, Weidmann E, Biskamp M, Gnjatic S, Pan L, Hoffman E, Old LJ, Knuth A, Jäger E. LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun. 2007 Oct 19;7:16.

Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, Schwarz SE, Hövelmann S, Göttlicher M, Knuth A, Jäger E.Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer. 2007 Jul 16;97(2):177-82.

Hartmann JT, Pintoffl JP, Al-Batran SE, Quietzsch D, Meisinger I, Horger M, Nehls O, Bokemeyer C, Königsrainer A, Jäger E, Kanz L. Mitomycin C plus Infusional 5-Fluorouracil in Platinum-Refractory Gastric Adenocarcinoma: An Extended Multicenter Phase II Study. Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study. Onkologie 2007 May;30(5):235-40.

Höhler T, Rödel C, Hölscher AH, Al-Batran SE. Neoadjuvante und palliative Therapie des Osophagus- und Magenkarzinoms.  Onkologie 2007; 30 Suppl 2 :23-26.

Al-Batran SE, Scholz M, Jäger E. Chemotherapy for Advanced Gastric Cancer.   J Clin Oncol 2007 Feb 20;25(6):729.

Karbach J, Gnjatic S, Pauligk C, Bender A, Maeurer M, Schultze JL, Nadler K, Wahle C, Knuth A, Old LJ, Jäger E. Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination. Int J Cancer. 2007 Nov 1;121(9):2042-8.

2006

Al-Batran SE, Bischoff J, von Minckwitz G, Atmaca A, Kleeberg U, Meuthen I, Morack G, Lerbs W, Hecker D, Sehouli J, Knuth A, Jäger E. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br J Cancer 2006 Jun 5; 94(11):1615-20.

Al-Batran SE, Meerpohl HG, von Minckwitz G, Atmaca A, Kleeberg U, Harbeck N, Lerbs W, Hecker D, Sehouli J, Knuth A, Jäger E. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology 2006; 70(2):141-6.

Hofheinz RD, Al-Batran SE, Hochhaus A, Jäger E, Reichardt VL, Fritsch H, Trommeshauser D, Munzert G. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res. 2010 Sep 15;16(18):4666-74. doi: 10.1158/1078-0432.CCR-10-0318. Epub 2010 Aug 3.

Karbach J, Pauligk C, Bender A, Gnjatic S, Franzmann K, Wahle C, Jäger D, Knuth A, Old LJ, Jäger E. Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011. Int J Cancer. 2006 Feb 1;118(3):668-74. Erratum in: Int J Cancer. 2006 Oct 1;119(7):1753.

Karbach J, Pauligk C, Bender A, Gnjatic S, Franzmann K, Wahle C, Jäger D, Knuth A, Old LJ, Jäger E. Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011. Int J Cancer. 2006 Feb 1;118(3):668-74. Erratum in: Int J Cancer. 2006 Oct 1;119(7):1753.

Friedmann I, Atmaca A, Chow KU, Jäger E, Weidmann E. Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer. J Chemother. 2006 Aug;18(4):415-20.

Goetze T, Paolucci V. Does laparoscopy worsen the prognosis for incidental gallbladder cancer? Surg Endosc. 2006 Feb;20(2):286-93.

2005

Al-Batran SE, Rafiyan MR, Atmaca A, Neumann A, Karbach J, Bender A, Weidmann E, Altmannsberger HM, Knuth A, Jäger E. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res 2005, 65(9):3937-41.

Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Dürk H, Rost A, Neise M, von Grünhagen U, Chow KU,  Hansmann ML, Hoelzer D, Mitrou PS. Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin’s Lymphoma.  J Clin Oncol 2005, 2:3383-9.

Von Minckwitz G, Harder S, Hovelmann S, Jäger E, Al-Batran SE, Loibl S, Atmaca A, Cimpoiasu C, Neumann A, Abera A, Knuth A, Kaufmann M, Jager D, Maurer AB, Wels WS. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res. 2005, 7(5):R617-26.

Wolschke C, Goekkurt E, Al-Batran SE, Hossfeld DK, Stoehlmacher J. Pharmacogenetics of extraordinary responses to 5-FU/cisplatin chemotherapy in advanced gastric cancer – report of 2 cases. Onkologie, 2005, 28(11):589-92.

T. Acker, A. Diaz-Juan, J. Aragones, M. Tjwa, K. Brusselmans, L. Moons, D. Fukumura, M. Paz Moreno-Murciano, J.-M. Herbert, A. Burger, J. Riedel, G. Elvert, I. Flamme, P.H. Maxwell, D. Collen, M. Dewerchin, R.K. Jain, K.H. Plate, P. Carmeliet (2005) “Genetic evidence for a tumor suppressor role of HIF-2α”, Cancer Cell 8, 131-141

Jäger D, Karbach J, Pauligk C, Seil I, Frei C, Chen YT, Old LJ, Knuth A, Jäger E. Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. Cancer Immun. 2005 Dec 12;5:11.

2004

Al-Batran S, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel JM, Seipelt G, Rost A, Orth J, Knuth J, Jäger E. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004, 15;22(4):658-63.

Eickhoff R, Jennemann G, Hoffbauer G, Schuring MP, Kaltner H, Sinowatz F, Gabius HJ, Seitz J. Immunohistochemical detection of macrophage migration inhibitory factor in fetal and adult bovine epididymis: release by the apocrine secretion mode? Cells Tissues Organs. 2006;182(1):22-31. Mol Hum Reprod. 2004 Aug;10(8):605-11. Epub 2004 May 28.

Al-Batran S, Atmaca A, Bert F, Jäger D, Frisch C, Neumann A, Orth J, Knuth A, Jäger E. Dose Escalation Study for Defining the Maximum Tolerated Dose of Continuous Oral Trofosfamide in Pre-treated Patients with Metastatic Lung Cancer. Onkologie 2004, 27(6):534-8.

Hartmann JT, Oechsle K, Jäger E, Reis HE, Haag C, Niederle N, Wilke HJ, Pfluger KH, Al-Batran SE, Buchele T, Hofheinz RD, Kanz L, Bokemeyer C. Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil. Anti-cancer Drugs 2004, 15(5):473-7.

Pauligk C, Nain M, Reiling N, Gemsa D, Kaufmann A. CD14 is required for influenza A virus-induced cytokine and chemokine production. Immunobiology. 2004;209(1-2):3-10.

V. Paolucci,  T. Götze. Prognose des okkulten Gallenblasenkarzinoms nach laparoskopischer und konventioneller Cholezystektomie. Chirurgisches Forum 2004 für experimentelle und klinische Forschung (Forumband 33)

2003

Hofheinz RD, Al-Batran SE, Hartmann F, Hartung G, Jäger D, Renner C, Tanswell P, Kunz U, Amelsberg A, Kuthan H, Stehle G. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 2003, 26(1):44-8.

Paolucci V, Neckell M, Gotze T. [Unsuspected Gallbladder carcinoma – The CAE-S/CAMIC registry] Zentralbl Chir. 2003 Apr;128(4):309-12.

2002

Gamarra F, Wagner S, Al-Batran S, Maier I, Castro M, Hautmann H, Bergner A, Baumgartner R, and Huber RM. Kinetics of 5-aminolevulinic acid-induced fluorescence in organ cultures of bronchial epithelium and tumor. Respiration 2002, 69(5):445-50.

Jäger E, Karbach J, Gnjatic S, Jäger D, Maeurer M, Atmaca A, Arand M, Skipper J, Stockert E, Chen YT, Old LJ, Knuth A. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.  Cancer Immun. 2002 Sep 19;2:12.

Jäger D, Stockert E, Karbach J, Herrlinger K, Atmaca A, Arand M, Chen YT, Gnjatic S, Old LJ, Knuth A, Jäger E. Urine antibody against human cancer antigen NY-ESO-1.  Cancer Immun. 2002 Aug 6;2:10.

2001

Kaufmann A, Salentin R, Meyer RG, Bussfeld D, Pauligk C, Fesq H, Hofmann P, Nain M, Gemsa D, Sprenger H. Defense against influenza A virus infection: essential role of the chemokine system. Immunobiology. 2001 Dec;204(5):603-13. Review.

Eickhoff R, Wilhelm B, Renneberg H, Wennemuth G, Bacher M, Linder D, Bucala R, Seitz J, Meinhardt A. Purification and characterization of macrophage migration inhibitory factor as a secretory protein from rat epididymis: evidences for alternative release and transfer to spermatozoa. Mol Med. 2001 Jan;7(1):27-35.

Eickhoff R, Baldauf C, Koyro HW, Wennemuth G, Suga Y, Seitz J, Henkel R, Meinhardt A. Influence of macrophage migration inhibitory factor (MIF) on the zinc content and redox state of protein-bound sulphydryl groups in rat sperm: indications for a new role of MIF in sperm maturation. Mol Med. 2001 Jan;7(1):27-35.

2000

Meinhardt A, Bacher M, Wennemuth G, Eickhoff R, Hedger M. Macrophage migration inhibitory factor (MIF) as a paracrine mediator in the interaction of testicular somatic cells. Andrologia. 2000 Jan;32(1):46-8

1999

Al-Batran S, Astner ST, Supthut M, Gamarra F, Brueckner K, Welsch U, Knuechel R, Huber RM. Three-dimensional in vitro cocultivation of lung carcinoma cells with human bronchial organ culture as a model for bronchial carcinoma. Am J Respir Cell Mol Biol 1999, 21:200-8.

1995

Dengler R, Münstermann U, Al-Batran S, Hausner I, Faderl S, Nerl C, Emmerich B. Immuncytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br J Haematol 1995, 89:250-57.